Adaptive Biotechnologies 3Q 2026: Revenue $83.9M, Net income $2.9M, EPS $0.02— 10-Q Summary
Adaptive Biotechnologies reported 3Q 2026 revenue of $83.9M, down 10.7% YoY, with net income of $2.9M and EPS of $0.02. MRD revenue grew 28% quarterly, offsetting the end of the Genentech collaboration. The company plans to separate its businesses and expects MRD revenue growth, while Immune Medicine revenue may decline.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger short‑term selling pressure, though the rise in MRD test volume could support future recovery.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for short‑term traders monitoring earnings surprises.
What to watch
Potential upside from expanded Medicare coverage for mantle cell lymphoma monitoring.
Background
Adaptive Biotechnologies disclosed its Q3 2026 results via a 10‑Q filing, noting a decline in overall revenue due to the end of a Genentech partnership but growth in MRD testing.
Ticker impact
Adaptive Biotechnologies reported Q3 2026 revenue of $83.9M, down 10.7% YoY and net income of $2.9M, indicating a earnings miss.
likely downward pressure as investors price in weaker revenue and reduced guidance
Revenue decline and lower net income are fresh disclosures that typically trigger sell‑offs in micro‑cap biotech stocks.
Market effects
Biotech sector may see modest pullback as earnings miss highlights reliance on collaborations.
US biotech investors may reassess exposure to companies with similar partnership structures.
Limited; primarily affects US-listed biotech micro‑caps.
Counterpoint
If the MRD revenue growth offsets the Genentech loss, the stock could be undervalued on a longer horizon.
Key entities
- companyAdaptive Biotechnologies
US‑listed biotech firm (ticker ADPT) reporting Q3 2026 earnings.
- partnerGenentech
Former collaboration partner whose contract ended, impacting revenue.


